JP:Q:Further classifications? A:AR+ is a predom subtype, 'tremendous progress in 2-3y among many groups' to be definitive #AACR15
7:48am April 19th 2015 via Hootsuite
JP: Food for thought: shows distribution of TNBC by ethnicity from '12 Nature ref. http://t.co/bro0VlSqtE #AACR15
7:46am April 19th 2015 via Hootsuite
JP: Want to diversify genomic information; a health disparity issue (both genetic and lifestyle determinants). Credits Komen, SPORE #AACR15
7:44am April 19th 2015 via Hootsuite
JP: Clearly TNBC has distinct subtypes; there is differential sens.; challenging to sort out, +'ive endpoints not a sure thing #AACR15
7:43am April 19th 2015 via Hootsuite
JP: Data on PI3K inhibitors increasing cisplatin efficacy. Leading to another trial BRE1287 PIb/II AR- TNBC for this #AACR15
7:41am April 19th 2015 via Hootsuite
JP: Now digging into genotype and Foundation Med data into PI3K pathway genes.. Of 42% cases evaluated, some 25 mut classes #AACR15
7:40am April 19th 2015 via Hootsuite
JP: Showed frequency of PI3K pathway mutation, and subtyping into their 7 classes from #TCGA datasets http://t.co/M2e7FZj7Up #AACR15
7:39am April 19th 2015 via Hootsuite
JP: (I'm really enjoying this 7am session on TNBC, Jennifer Pietenpol of Vanderbilt is a great #scicomm presenter.) #AACR15
7:37am April 19th 2015 via Hootsuite
JP: But only 10% of TNBC are AR+; it will take a while to determine more subtypes. '12 Nature ref http://t.co/sc2TaW9i3n more clues #AACR15
7:35am April 19th 2015 via Hootsuite
JP: High freq of PIK3CA in AR+ TNBC; '14 ref http://t.co/nphBuqwoSG Using this info for PIb/II study for Taselisib (GDC-0032) #AACR15
7:34am April 19th 2015 via Hootsuite
JP: Classified 30 TNBC cell lines to subtypes, in order to use as xenograft model to look at new therapies. #AACR15
7:30am April 19th 2015 via Hootsuite
JP: Now with other data (incl RPPA from Mills at MDA) '14 ref http://t.co/QQSTJeZ68c showed subtype breakdown of 163 smpls, mean DFS #AACR15
7:29am April 19th 2015 via Hootsuite
JP: Highlighting work w/Brown, Chang labs ref '15 http://t.co/zjh7G91mA0 RNA analysis of 198 TNBC tumors, four sub-types. #AACR15
7:27am April 19th 2015 via Hootsuite
JP: Work on 7 TNBCtype results 2013 ref http://t.co/xpNh1BY7Ip #AACR15
7:25am April 19th 2015 via Hootsuite
JP: K-M curve of TNBCtype an independent predictor of pCR to seq. taxane & anthracycline regimens. BL1/2 subtypes diff response #AACR15
7:23am April 19th 2015 via Hootsuite
JP: Developed a subtyping tool TNBCtype 2012 ref http://t.co/BRzELNhDUH 50% industry, 50% acad participation #AACR15
7:22am April 19th 2015 via Hootsuite
JP: Looked at RNA-Seq from tumor / stroma between responders / non-resp - striking differences (unpubl) #AACR15
7:19am April 19th 2015 via Hootsuite
JP: Back to the trial: had smpls & progress on 133. Overall: 43% had complete response at time of surgery, had NED. 2 arms - caveats #AA
7:18am April 19th 2015 via Hootsuite
JP: Had a training set & validation set, expression profile heatmaps clear. Described details of classes: heterogeneity was extreme #AAC
7:14am April 19th 2015 via Hootsuite
JP:Genomic datasets biased US/EU. 7 classes: 2 basal-like, immunomod, mesenchymal, mes/stem-like, luminal/androgen receptor #AACR15
7:12am April 19th 2015 via Hootsuite
JP: During 2y trial - examined whether TNBC could be sub-typed. 21 datasets, 8 countries, 800 samples, same platform. 587 ID'd #AACR15
7:10am April 19th 2015 via Hootsuite
JP: Randomized PII trial in SII/III TNC (Cisplatin + Paclitaxel +/- RAD001 (everolimus) - det if genomic profiling provides insight #AACR15
7:09am April 19th 2015 via Hootsuite
JP: Major need for new therapies. Publication from 2001 PNAS w/p53 signalling arm http://t.co/VYLNjOtCLM #AACR15
7:08am April 19th 2015 via Hootsuite
JP: Great illustration of intra- and inter-tumor heterogeneity http://t.co/mwKrRDeZkK #AACR15
7:06am April 19th 2015 via Hootsuite
JP: 35K new cases/y; 25% in AA, 17% Hispanics, 12% Asian, 11% Caucasian. Most common w/BRCA1, poor prognosis, no targeted therapies #AACR15
7:03am April 19th 2015 via Hootsuite
JP: TNBC is a disease for what it is not - and "we need to understand it better in order to better provide precision care" #AACR15
Jennifer Pietenpol (Vanderbilt) “New strategies for triple-negative breast cancer - deciphering the hetergeneity” JP #AACR15
7:02am April 19th 2015 via Hootsuite
RT @embatty: Clive Brown talking about MinION Mk II, reading 500 bases per second for a 40Gb run #pmwcuk15
7:00am April 19th 2015 via Hootsuite
RT @JAMA_current: Reforming @WHO After #Ebola http://t.co/rwgoXcoOHr
6:05am April 19th 2015 via Hootsuite
RT @JAMA_current: The personal health information of patients in the #US is not safe, and it needs to be http://t.co/UIFlgXo5Pa
5:00am April 19th 2015 via Hootsuite
RT @PlantEvolution: Epigenome editing with a CRISPR-Cas9-based acetyltransferase @NatureBiotech http://t.co/pt3vxXvylT
4:15am April 19th 2015 via Hootsuite
How Syrians Saved an Ancient Seedbank From Civil War | WIRED http://t.co/oS6srDSzMe
10:20pm April 18th 2015 via Hootsuite
National Geographic documentary "World's Smart Cities" on San Diego | http://t.co/91lMA5PQt8 http://t.co/QfR1X3xgOk
9:55pm April 18th 2015 via Hootsuite
One Way to Get Unstuck and Move Up? All You Have to Do Is Ask - WSJ http://t.co/TIgkIM6vKn
8:55pm April 18th 2015 via Hootsuite
Today’s Personality Tests Raise the Bar for Job Seekers - WSJ http://t.co/mFBXLUowyz
7:55pm April 18th 2015 via Hootsuite
DB: 155 up-regulates immunity by downreg inhibitory phosphatase; 125b stimulates prod of stem cells. And any can cause leukemia. #AACR15
6:17pm April 18th 2015 via Hootsuite
DB: miRNAs play critical regulatory roles, with their own pathways. 146a modulates inflamm. 132 buffers transc factor #AACR15
DB: Onto miR-155 and miR-146a and NF-kB signaling. When 146a knocked out - develops myeloid ca. due to lack of feedback reg of NFkB #AACR15
6:13pm April 18th 2015 via Hootsuite
DB: Onto miR-125b: overexp. triggers myeloproliferative disease. Major effect on stem cell dominance, normally down-reg. #AACR15
6:09pm April 18th 2015 via Hootsuite
DB: Created a vector to co-express FOXO3 w/mIR-132, and overcomes mIR-132 inhibition. #AACR15
6:01pm April 18th 2015 via Hootsuite
.@notSoJunkDNA I was thinking the same thing - may well have been a typo (it was printed on his slide)
5:59pm April 18th 2015 via Hootsuite in reply to notSoJunkDNA
DB: (Unpubl. work): miR-132 is enriched in hematopoetic stem cells. Mice treated w/5-FU, get HPSCs & infect w/miR-132 vector #AACR15
5:53pm April 18th 2015 via Hootsuite
DB: The Q- when NF-kB active, what genes get turned on? Found 3 endo-toxin responsive miRNA genes (3/4 he's talking about) #AACR15
5:51pm April 18th 2015 via Hootsuite
DB:miR-146a inflammation, and mIR-155. Digress to NF-kB, a pleiotropic regulator of gene exp. Dimer active when inhibitor lost #AACR15
5:49pm April 18th 2015 via Hootsuite
DB: miRNAs have multiple targets. Shows tree of hematopoetic cell fate. Will be talking about miR-132 stem cell health, miR-125b ALL #AACR15
5:48pm April 18th 2015 via Hootsuite
DB: miRNAs transcribed from RNAPolII just like mRNA; cleaved & put into RISC, looks for 8-nt homology; est ~300 miRNA in humans #AACR15
5:46pm April 18th 2015 via Hootsuite
DB: The suspicion of an RNA World is now dogma; miRs in cancer, but also all elements of metabolism involved with cancer. #AACR15
5:44pm April 18th 2015 via Hootsuite
DB: Cover of Economist: "Biology's Big Bang" from 2007. In 15y: how many small RNAs that play regulatory roles. miRNAs, lincRNAs... #AACR15
5:42pm April 18th 2015 via Hootsuite
DB: Genes regulated by transcription factors, ncRNA mainly adjuncts to protein synthesis. Then hints: Ad VA RNA, spliceosomes #AACR15
5:41pm April 18th 2015 via Hootsuite
DB: (He was a non-smoker.) His work on Ras sarcoma virus set the stage to find first oncogenes. #AACR15
5:39pm April 18th 2015 via Hootsuite
